Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fiona Taylor

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Clinical Chemistry|June 27, 2018
Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts SurvivalShobha Silva, Sarah Danson, Dawn Teare, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trialJohn M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2020
Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716Sarah J Danson, Joe Conner, John G Edwards, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 24, 2024
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approachDaniel Serrano, David Cella, Don Husereau, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 26, 2024
Sarcopenia is independently associated with poor preoperative physical fitness in patients undergoing colorectal cancer surgeryJason Rai, Edward T Pring, Katrina Knight, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
Molecular Genetics & Genomic Medicine|January 8, 2019
Atypical nested 22q11.2 duplications between LCR22B and LCR22D are associated with neurodevelopmental phenotypes including autism spectrum disorder with incomplete penetranceKaren J Woodward, Julie Stampalia, Hannah Vanyai, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Clinical Chemistry|June 27, 2018
Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts SurvivalShobha Silva, Sarah Danson, Dawn Teare, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trialJohn M Kirkwood, Peter Mohr, Christoph Hoeller, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2020
Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716Sarah J Danson, Joe Conner, John G Edwards, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 24, 2024
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approachDaniel Serrano, David Cella, Don Husereau, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 26, 2024
Sarcopenia is independently associated with poor preoperative physical fitness in patients undergoing colorectal cancer surgeryJason Rai, Edward T Pring, Katrina Knight, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
Molecular Genetics & Genomic Medicine|January 8, 2019
Atypical nested 22q11.2 duplications between LCR22B and LCR22D are associated with neurodevelopmental phenotypes including autism spectrum disorder with incomplete penetranceKaren J Woodward, Julie Stampalia, Hannah Vanyai, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Pageof 9